Search Results
Treatment Selection for Relapsed Multiple Myeloma: CAR-T Versus Bispecifics
How to Treat Relapse and Choose CAR T or Bispecific Antibodies for MM - 2024 Blood Cancer OncTalk
Bispecific Versus CAR T-Cell Therapy for Myeloma and Bridging Therapy Needs for CAR-T
Myeloma Treatment Selection: CAR-T Versus Bispecific T-Cell Engagers, Bridging Therapy Options
Treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
Factors influencing treatment selection for patients with relapsed multiple myeloma
CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023
CAR T Cell Therapy & Bispecifics: Cutting Edge Treatment in Myeloma | Dr. Joseph Mikhael
Addressing Current Questions and Controversies in the Management of Multiple Myeloma
CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?
Strategies for Combatting Myeloma Relapse Effectively #cancerresearch
Hitting the BCMA Target in Multiple Myeloma
